Pharmaceutical Biotechnology Research

Biosimilars

Biosimilar medicines may provide cost savings for patients who can benefit from biologic medicines. By potentially providing more affordable options, biosimilar medicines can allow for the reallocation of resources to other areas of patient care. Sensitivity of Biosimilars is high i.e. the temperature plays a big role in their maintenance. Hence, they have to be distributed through a cold chain network. 2. Their development costs are much more as compared to the generic drugs.

Biosimilars are also used to treat other medical conditions. For example, adalimumab (Humira) is used to treat conditions including arthritis, Crohn's disease and ulcerative colitis. Biosimilars for this drug include Imraldi, Amgevita, Hyrimoz, Idacio, and Yuflyma. For equal efficacy and safety, biosimilar drugs require much less research and development than their reference biologics, since they are a very similar copy. This means they are much cheaper to produce. The money saved can be reinvested.